bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) was the target of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 396,800 shares, a drop of 7.2% from the January 15th total of 427,500 shares. Based on an average trading volume of 172,600 shares, the days-to-cover ratio is presently 2.3 days. Currently, 4.2% of the company’s stock are sold short.
bioAffinity Technologies Trading Down 2.2 %
Shares of NASDAQ BIAF opened at $0.79 on Wednesday. bioAffinity Technologies has a 1-year low of $0.57 and a 1-year high of $3.62. The business has a fifty day moving average price of $0.85 and a 200 day moving average price of $1.32. The stock has a market capitalization of $12.25 million, a P/E ratio of -0.96 and a beta of 2.95. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01.
Institutional Trading of bioAffinity Technologies
A hedge fund recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC increased its position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) by 131.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,304 shares of the company’s stock after acquiring an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned about 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.64% of the company’s stock.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Featured Articles
- Five stocks we like better than bioAffinity Technologies
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Following Congress Stock Trades
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Golden Cross Stocks: Pattern, Examples and Charts
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
